CNSP
CNS Pharmaceuticals, Inc.
$5.07
+0.39 (+8.33%)
At close · Jul 2
Market Cap
$7.41M
Shares
1,461,449
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.07
Open$5.02
Day$4.66–5.07
52W$1.90–12.36
Avg vol 30d52K
Short int39K · 2.6% float · 1.8d
Short vol41%
Last earningsApr 1, 2024
DataJan 2020–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−8% below
+
Price vs 50-day avg
+7% above
◦
RSI (14)
57 · neutral
+
MACD trend
positive
◦
52-week position
30% · mid-range
Sentiment · smart money
Very Bullish
◦
Trend (MA cross)
50d $5 › 200d $5 — 200d above 50d
+
Institutional flow
+22% holders QoQ · +4 funds added
+
Insider flow
Net +$34.0K over 90 days · 0% sells
+
Short interest
2.65% of float · ▼ -20.3% MoM · 1.8 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
11 holders — near 1-yr high, broad support
Fundamentals
Strong
+
EPS growth
+92% Y/Y
−
Free cash flow
$-13.8M
+
Balance sheet
net cash $7.2M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−8% below
Bearish
Price vs 50-day avg
+7% above
Bullish
RSI (14)
57 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
30% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+22% holders QoQ · +4 funds added
Insider flow
Accumulating
Net +$34.0K over 90 days · 0% sells
Short interest
Falling
2.65% of float · ▼ -20.3% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
11 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $5 · 30%
52-wk high $12
vs 200-day avg -8%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CNSP
this stock
CNS Pharmaceuticals, Inc.
|
$7.41M | -3.4% | — | — | 2.6% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CNSP | +22.1% | -3.2% | -14.7% | +6.1% | -3.4% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +20.7% | -2.0% | -22.7% | +6.3% | -12.7% |